Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Characteristics, Treatment And Survival Outcomes In Malignant Pleural Mesothelioma: An Institutional Experience In Turkey.

M. Kuçukoner, M. Ali Kaplan, A. Inal, Z. Urakçı, O. Abakay, A. Cetin Tanrikulu, A. Abakay, Hatice Selim Sen, Gul Turkcu, A. Şenyiğit, H. Buyukbayram, A. Isikdogan
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To compare treatment modalities and investigate potential prognostic factors for survival in patients with malignant pleural mesothelioma (MPM). METHODS The present study has investigated the data of 150 patients with MPM who were examined and treated in our center from 2005 to 2012. RESULTS The study included 87 male (58% and 63 female (42) patients. Surgical resection (pleurectomy/decortications (P/D), and extrapleural pneumonectomy (EPP)) was performed in 32 (36.7%) patients; 87 patients (58%) received chemotherapy alone and 16 (10.7%) had surgery, chemotherapy and radiotherapy (trimodal treatment). The median progression free and overall survival (PFS and OS) for all patients were 10.6 and 14.8 months, respectively. No statistically significant difference was observed between the patients who received pemetrexed/cisplatin (N=54) and gemcitabine/cisplatin (N=28) in terms of PFS and OS (p=0.145, p=0.244, respectively). Also, no statistically significant difference was registered between operated and non operated patients (PFS and OS, p=0.416, p=0.095, respectively). There was no difference in both PFS and OS rates between patients who had P/D or EPP (p=0.87, p=0.652, respectively). Log rank analysis: Eastern Cooperative Oncology Group performance status (ECOG PS) (p=0.018), histology (p<0.001), stage (p<0.001) and leukocytosis (p=0.005) were found to be significant prognostic factors of OS. At multivariate analysis, ECOG PS (p=0.016) and stage (p<0.001) were independent prognostic factors for OS. CONCLUSION Median OS was approximately 1 year. ECOG PS, histological type, stage and presence of leukocytosis were prognostic factors that affected both PFS and OS. EPP or P/D surgical options did not provide difference in terms of survival. Survival rates in patients who received a combination of platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were similar.
This paper references
Treatment of malignant pleural mesothelioma
A. Alolayan (2010)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.4103/0970-2113.85688
Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma
A. Abakay (2011)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.3109/07357909009017560
Comprehensive criteria for assessing therapy-induced toxicity.
J. Ajani (1990)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1007/s12199-007-0017-6
Pathology of mesothelioma
K. Inai (2008)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
Eds): Practical Clinical Oncology (1st Edn)
L Hanna (2012)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1016/J.THORSURG.2004.06.007
Pathology of mesothelioma.
J. M. Corson (2004)
10.5152/gghs.2015.072
Benign and Malignant (Except Mesothelioma) Tumors of The Pleura
Serkan Uysal (2015)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
10.1097/01.JTO.0000283754.00846.9C
P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice
C. Lee (2007)
10.1378/CHEST.93.2.443B
Extrathoracic lymph node metastases in malignant pleural mesothelioma.
M. Huncharek (1988)
10.1007/s12032-012-0276-y
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients
E. T. Elkıran (2012)
10.1017/CBO9780511545375
Practical Clinical Oncology: Acknowledgements
L. Hanna (2008)
The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia.
A. I. Carkanat (2011)
10.1378/chest.32.3.340
Malignant mesothelioma of the pleura.
A. Tramujas (1957)
Diffuse Malignant Mesothelioma. In: Shields TW (Ed): General Thoracic Surgery (5th Edn)
W. Rush (2000)
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1002/cncr.26143
Circulating and tumor‐infiltrating myeloid cells predict survival in human pleural mesothelioma
B. Burt (2011)
10.1378/CHEST.107.6_SUPPLEMENT.345S
Mesothelioma and radical multimodality therapy: who benefits?
D. Sugarbaker (1995)
10.Diffuse Malignant Mesotheliomaの1例(第721回 千葉医学会例会・第19回 肺癌研究施設例会)
光永 伸一郎 (1985)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1007/s11864-011-0154-4
Surgical Treatment of Malignant Pleural Mesothelioma
A. Kaufman (2011)
10.2131/JTS.33.105
Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube.
A. Takagi (2008)
10.1378/CHEST.70.1.43
Pleural calcification associated with exposure to chrysotile asbestos in southeast Turkey.
S. Yazicioglu (1976)
10.1053/HUPA.2002.128248
Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.
N. Ordóñez (2002)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Diffuse malignant mesothelioma of the pleural space and its management.
L. Zellos (2002)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.1186/1750-1172-3-34
Malignant mesothelioma
A. Moore (2008)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1097/00000421-198212000-00014
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar